✦ LIBER ✦

Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma

✍ Scribed by Chi-Chang Chen; Gregory P. Hess; Zhimei Liu; Dean H. Gesme; Sanjiv S. Agarwala; Carlos C. Garay; Jerrold W. Hill; Amy Guo

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Economic evaluation of sunitinib malate

✍ Timo Purmonen; Janne A. Martikainen; Erkki J.O. Soini; Vesa Kataja; Riikka-Liisa 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 839 KB

Third-Line Sorafenib After Sequential Th

✍ Giuseppe Di Lorenzo; Carlo Buonerba; Piera Federico; Pasquale Rescigno; Michele 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 242 KB

Tolerability of first-line therapy for m

✍ Camillo Porta; Cezary Szczylik 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 321 KB

Cost-effectiveness evaluation of sunitin

✍ Emiliano Calvo Aller; Pablo Maroto; Noémi Kreif; José Luis González Larriba; Mar 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 451 KB

PCN15 COST-EFFECTIVENESS OF NEW TARGETED

✍ EC Aiello; N Muszbek; E Richardet; A Lingua; C Charbonneau; E Remák 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

PCN46 PHARMACOECONOMIC EVALUATION OF SUN

✍ C Tenorio; J Vargas; P Rizo-Rios; O Flores-Gil; J Martínez-Fonseca; J Mould-Quev 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB